The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure.
about
Adenosine receptors as therapeutic targetsTranslocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathwaysRecent developments in adenosine receptor ligands and their potential as novel drugsSynthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptorTreatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists.Polyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide.Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moietyStructure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptorFunctionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y ReceptorsStructure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.Introduction to adenosine receptors as therapeutic targets.Purine receptors: GPCR structure and agonist design"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonistsStructure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists.Action of nucleosides and nucleotides at 7 transmembrane-spanning receptors.Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists.Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species.Therapeutic potential of adenosine receptor antagonists and agonists.Adenosine receptor targeting in health and disease.The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study.Structural Probing and Molecular Modeling of the A₃ Adenosine Receptor: A Focus on Agonist Binding.Ocular Purine Receptors as Drug Targets in the Eye.
P2860
Q24632095-B7401851-3E80-4691-A9C0-51FCAF17CBFAQ24646643-0C31AF1D-F18F-42C0-9416-E1768D0BED04Q27687253-C2C33B2D-CAAC-49F5-9CFB-82970E4F848FQ33516043-C1D80020-18AB-45F5-AA3F-C5A5F44FCDDBQ33543585-23AD583D-CD6E-4CFD-B786-1A43AA6E03E2Q33638882-55E9EC63-083F-42D2-90B5-92AF33D5B575Q33754704-662FCD56-E5D5-44D6-890A-3FC7BD0DA357Q34313641-4A41D30A-A958-441C-B7C4-E2335BE8D0EAQ34676680-E26E79FD-B425-4EDE-8512-790B95B2A2F6Q34975607-A6F43604-8543-4B07-A42D-B1BAF9A82382Q35029175-A6B80535-FA07-4B32-94B8-A3B00A3E8C70Q35580301-93B604DC-8F2A-4529-89DD-05F92AB76B38Q36021597-6DA9E00A-8D6D-46EF-B99F-04BB1A378248Q36146803-0162B4B1-CA7B-471F-915A-ECB93CC4EDADQ36153376-829A7F60-BB6A-4A67-8900-78F94D730BDEQ36161738-80AF01DE-8AA8-416D-B2A4-8AC62AF5464CQ36327179-DA13C954-0556-41E8-9C47-653956D8F17FQ36627486-E8777512-3A38-4A12-942A-ABFC850DA6DCQ36635966-3E5B8354-FE06-42DA-9A44-D26CD219D3C8Q36996182-2746BC4D-6833-4412-BBFD-1D5390E1D267Q37143158-DD115D91-2E97-413C-9FDF-5D90E5B881CFQ37461055-42E772AF-9A9B-4C30-93D8-A0F88BB9B9D0Q37689793-992CD15D-C384-4F25-A5BF-1A13DF3488E9Q37948081-DC064F4A-3CE0-4957-9C7F-68EDC097AE8DQ37957791-CFDC2BEB-BA4C-4E64-9094-5E68885A4257Q38584194-1A6E0DAA-7B56-4875-9B7E-8E13FC019195Q38649750-B7882BFF-155B-4BD7-83B1-1EDEAEEC616BQ38911603-A577052F-9673-478E-904B-C01B3C6BE946Q41651208-834D042E-C03F-4472-97DF-89B1D1D8BCC3
P2860
The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The cross-species A3 adenosine ...... es mouse intraocular pressure.
@ast
The cross-species A3 adenosine ...... es mouse intraocular pressure.
@en
type
label
The cross-species A3 adenosine ...... es mouse intraocular pressure.
@ast
The cross-species A3 adenosine ...... es mouse intraocular pressure.
@en
prefLabel
The cross-species A3 adenosine ...... es mouse intraocular pressure.
@ast
The cross-species A3 adenosine ...... es mouse intraocular pressure.
@en
P2093
P2860
P1433
P1476
The cross-species A3 adenosine ...... es mouse intraocular pressure.
@en
P2093
Kenneth A Jacobson
Kim Peterson-Yantorno
Miguel Coca-Prados
Mortimer M Civan
Richard A Stone
P2860
P304
P356
10.1080/02713680590953147
P50
P577
2005-09-01T00:00:00Z